A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

Completed · Phase 2 · Has a placebo group

Conditions studied: Alopecia, Alopecia, Androgenetic, Baldness

In brief

This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).

Key facts

Study ID

NCT01904721

Run by

Allergan

People needed

244

Starts

2013-08-01

Expected to finish

2015-01-01

Last updated by the study team

2016-03-22

Who can join

Age: 18 and older, up to 49. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year
• Willingness to maintain same hair style, length and hair color during study
• Willingness to have micro-dot-tattoo applied to scalp (Stage 2 only)

You may not qualify if…

• Drug or alcohol abuse within 12 months
• HIV positive
• Received hair transplants or had scalp reductions
• Use of hair weaves, hair extensions or wigs within 3 months
• Use of minoxidil (oral or topical) and/or low level light treatment "combs" for hair growth within the last 6 months, or expected use during the study
• Application of topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to scalp within 4 weeks

Where it is running

• Study site — Fridley, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.